These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29292224)

  • 21. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes.
    Xin BT; de Bruin G; Huber EM; Besse A; Florea BI; Filippov DV; van der Marel GA; Kisselev AF; van der Stelt M; Driessen C; Groll M; Overkleeft HS
    J Med Chem; 2016 Aug; 59(15):7177-87. PubMed ID: 27438186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).
    Klein M; Busch M; Friese-Hamim M; Crosignani S; Fuchss T; Musil D; Rohdich F; Sanderson MP; Seenisamy J; Walter-Bausch G; Zanelli U; Hewitt P; Esdar C; Schadt O
    J Med Chem; 2021 Jul; 64(14):10230-10245. PubMed ID: 34228444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
    Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads.
    Kollár L; Gobec M; Proj M; Smrdel L; Knez D; Imre T; Gömöry Á; Petri L; Ábrányi-Balogh P; Csányi D; Ferenczy GG; Gobec S; Sosič I; Keserű GM
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and Biochemical Evaluation of Warhead-Decorated Psoralens as (Immuno)Proteasome Inhibitors.
    Schiffrer ES; Proj M; Gobec M; Rejc L; Šterman A; Mravljak J; Gobec S; Sosič I
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33445542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of selective fragment-sized immunoproteasome inhibitors.
    Kollár L; Gobec M; Szilágyi B; Proj M; Knez D; Ábrányi-Balogh P; Petri L; Imre T; Bajusz D; Ferenczy GG; Gobec S; Keserű GM; Sosič I
    Eur J Med Chem; 2021 Jul; 219():113455. PubMed ID: 33894528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
    Kasam V; Lee NR; Kim KB; Zhan CG
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3614-7. PubMed ID: 24913713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1,2,4-Oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome.
    Maréchal X; Genin E; Qin L; Sperandio O; Montes M; Basse N; Richy N; Miteva MA; Reboud-Ravaux M; Vidal J; Villoutreix BO
    Curr Med Chem; 2013; 20(18):2351-62. PubMed ID: 23531222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides.
    Zhan W; Singh PK; Ban Y; Qing X; Ah Kioon MD; Fan H; Zhao Q; Wang R; Sukenick G; Salmon J; Warren JD; Ma X; Barrat FJ; Nathan CF; Lin G
    J Med Chem; 2020 Nov; 63(21):13103-13123. PubMed ID: 33095579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
    Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
    Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoproteasome and Non-Covalent Inhibition: Exploration by Advanced Molecular Dynamics and Docking Methods.
    Culletta G; Zappalà M; Ettari R; Almerico AM; Tutone M
    Molecules; 2021 Jul; 26(13):. PubMed ID: 34279386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substituted quinolines as noncovalent proteasome inhibitors.
    McDaniel TJ; Lansdell TA; Dissanayake AA; Azevedo LM; Claes J; Odom AL; Tepe JJ
    Bioorg Med Chem; 2016 Jun; 24(11):2441-2450. PubMed ID: 27112450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a new series of amides as non-covalent proteasome inhibitors.
    Scarbaci K; Troiano V; Micale N; Ettari R; Tamborini L; Di Giovanni C; Cerchia C; Grasso S; Novellino E; Schirmeister T; Lavecchia A; Zappalà M
    Eur J Med Chem; 2014 Apr; 76():1-9. PubMed ID: 24561716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome.
    Hovhannisyan A; Pham TH; Bouvier D; Qin L; Melikyan G; Reboud-Ravaux M; Bouvier-Durand M
    Bioorg Med Chem Lett; 2013 May; 23(9):2696-703. PubMed ID: 23541650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of novel proteasome inhibitors based on phthalazinone scaffold.
    Yang L; Wang W; Sun Q; Xu F; Niu Y; Wang C; Liang L; Xu P
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2801-2805. PubMed ID: 27158142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
    Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
    J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New C(4)- and C(1)-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform.
    Hovhannisyan A; Pham TH; Bouvier D; Piroyan A; Dufau L; Qin L; Cheng Y; Melikyan G; Reboud-Ravaux M; Bouvier-Durand M
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1571-80. PubMed ID: 24534487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.